Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CD4-IgG2 (PRO 542)
CD4-IgG2 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| CD4-IgG2 (PRO 542) | DRUG | - |
Inclusion Criteria: * Confirmed diagnosis of HIV * Patients must be on a stable dose of acceptable anti-HIV therapy or receiving no anti-HIV therapy for at least four (4) weeks prior to the start of this study * HIV-1 determination by RNA-PCR greater than or equal to 100,000 copies/ml * CD4 count \...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
CD4-IgG2 is an investigational therapy being studied for the treatment of HIV infections, including acquired immune deficiency syndrome. It was evaluated in a Phase 2 clinical trial in HIV-infected patients. It is not approved for commercial use and remains in clinical development.
CD4-IgG2 is being developed by Lantheus Holdings, Inc., which trades on the Nasdaq under the ticker symbol LNTH. The company sponsored the Phase 2 trial of the drug in HIV-infected patients.
CD4-IgG2 is in Phase 2 development. One Phase 2 trial has been completed, and there are no active trials at this time. The drug is investigational and has not been approved by the FDA for any indication.
CD4-IgG2 has been studied in one completed Phase 2 trial, NCT00055185, titled Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients. The trial enrolled 24 participants in the United States and included adults 18 years and older.
Yes, CD4-IgG2 is also known as PRO 542. The alternative name appears in the trial title for NCT00055185, which evaluated PRO 542 in HIV-infected patients. Both names refer to the same investigational drug candidate.